drugset / Trial / NCT05320588
A Study in Patients With Advanced Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Timeline
- Start
- 2022-03-25
- Primary completion
- 2024-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIO-106 | Other / unclassified | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |